OSR (NASDAQ:OSRH) Trading Down 25.1% – Here’s Why

Posted by Brian Himes on Aug 14th, 2026

OSR Holdings, Inc. (NASDAQ:OSRH – Get Free Report)’s share price traded down 25.1% during mid-day trading on Wednesday . The company traded as low as $0.2507 and last traded at $0.2890. Approximately 2,807,246 shares traded hands during mid-day trading, an increase of 329% from the average daily volume of 654,724 shares. The stock had previously closed at $0.3860.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of OSR in a research note on Wednesday, June 24th. Wall Street Zen upgraded shares of OSR from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Check Out Our Latest Analysis on OSR

OSR Price Performance

The stock has a market capitalization of $11.10 million, a P/E ratio of -0.96 and a beta of 0.56. The firm has a 50-day simple moving average of $0.39 and a 200 day simple moving average of $0.47.

OSR (NASDAQ:OSRH – Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.02) earnings per share for the quarter. OSR had a negative return on equity of 7.24% and a negative net margin of 363.26%.The firm had revenue of $0.32 million for the quarter.

Institutional Investors Weigh In On OSR

A hedge fund recently bought a new stake in OSR stock. Susquehanna International Group LLP purchased a new stake in OSR Holdings, Inc. (NASDAQ:OSRH – Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned 0.37% of OSR as of its most recent filing with the Securities and Exchange Commission. 55.30% of the stock is owned by institutional investors and hedge funds.

OSR Company Profile

(Get Free Report)

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.